82,537 Shares in MEDNAX, Inc. (NYSE:MD) Acquired by Bridgewater Associates LP

Bridgewater Associates LP purchased a new position in MEDNAX, Inc. (NYSE:MD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 82,537 shares of the company’s stock, valued at approximately $2,488,000. Bridgewater Associates LP owned about 0.10% of MEDNAX at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Eagle Bay Advisors LLC acquired a new stake in shares of MEDNAX in the second quarter worth $30,000. Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of MEDNAX by 71.2% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,411 shares of the company’s stock worth $43,000 after purchasing an additional 587 shares during the period. Cullen Frost Bankers Inc. bought a new position in shares of MEDNAX in the second quarter worth about $50,000. Captrust Financial Advisors increased its stake in MEDNAX by 1,207.3% during the first quarter. Captrust Financial Advisors now owns 2,157 shares of the company’s stock valued at $55,000 after acquiring an additional 1,992 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in MEDNAX by 39.3% during the second quarter. PNC Financial Services Group Inc. now owns 4,664 shares of the company’s stock valued at $140,000 after acquiring an additional 1,316 shares during the period.

Shares of NYSE:MD opened at $26.49 on Thursday. MEDNAX, Inc. has a 52 week low of $12.47 and a 52 week high of $35.67. The firm’s fifty day moving average is $30.51 and its 200-day moving average is $29.72. The firm has a market cap of $2.29 billion, a PE ratio of -42.05, a price-to-earnings-growth ratio of 1.15 and a beta of 2.18. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.14 and a current ratio of 2.14.

MEDNAX (NYSE:MD) last posted its quarterly earnings results on Friday, August 6th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.09. The firm had revenue of $473.00 million during the quarter, compared to the consensus estimate of $453.12 million. MEDNAX had a negative net margin of 2.93% and a positive return on equity of 12.13%. The business’s revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 earnings per share. Sell-side analysts forecast that MEDNAX, Inc. will post 1.31 EPS for the current year.

MD has been the topic of several recent analyst reports. Truist reduced their target price on MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a report on Wednesday. Truist Securities lowered their price objective on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a research report on Wednesday. SVB Leerink started coverage on shares of MEDNAX in a research note on Monday, September 27th. They issued a “market perform” rating and a $29.00 target price for the company. Stifel Nicolaus assumed coverage on shares of MEDNAX in a research note on Tuesday, June 22nd. They issued a “hold” rating for the company. Finally, Mizuho increased their price objective on shares of MEDNAX from $30.00 to $32.00 and gave the stock a “neutral” rating in a research note on Monday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, MEDNAX has a consensus rating of “Hold” and an average price target of $29.00.

In related news, CEO Mark S. Ordan sold 95,000 shares of the company’s stock in a transaction that occurred on Monday, August 30th. The shares were sold at an average price of $35.09, for a total transaction of $3,333,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roger Md Medel sold 1,270 shares of the company’s stock in a transaction on Monday, October 4th. The shares were sold at an average price of $29.00, for a total transaction of $36,830.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,069 shares of company stock worth $3,655,028. 2.80% of the stock is owned by corporate insiders.

MEDNAX Company Profile

MEDNAX, Inc provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.

Further Reading: Yield Curve

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX, Inc. (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.